Apple Vision Pro Gains FDA Clearance for Surgical Use in Hip Arthroscopy
Apple's Vision Pro headset is finding a new application in operating rooms. Stryker announced that its SportSuite Vision software, designed for the Apple Vision Pro, has received De Novo authorization from the U.S. Food and Drug Administration (FDA). The authorization, granted in July, clears the way for surgeons to use the mixed-reality device during hip arthroscopy procedures.
The SportSuite Vision platform allows surgical teams to overlay procedural guidance, imaging data, and other critical information directly into the surgeon's field of view. By displaying this information hands-free within the surgical environment, the technology aims to improve workflow efficiency and reduce the need for surgeons to look away from the operative field to reference separate monitors.
The FDA's De Novo classification is typically reserved for novel medical devices that represent low-to-moderate risk and have no predicate device on the market to reference. This authorization marks one of the more prominent clearances for Apple Vision Pro in a clinical surgical setting, signaling growing adoption of consumer-grade mixed-reality hardware in specialized medical applications.
Stryker, a major player in orthopedic surgery, developed the SportSuite application specifically for use with the Vision Pro, leveraging the headset's high-resolution displays and spatial computing capabilities to support surgeons during procedures.